361 related articles for article (PubMed ID: 25896455)
1. The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding.
Mohr PG; Deng YM; McKimm-Breschkin JL
Virol J; 2015 Apr; 12():67. PubMed ID: 25896455
[TBL] [Abstract][Full Text] [Related]
2. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
Tamura D; Nguyen HT; Sleeman K; Levine M; Mishin VP; Yang H; Guo Z; Okomo-Adhiambo M; Xu X; Stevens J; Gubareva LV
Antimicrob Agents Chemother; 2013 Dec; 57(12):6141-6. PubMed ID: 24080660
[TBL] [Abstract][Full Text] [Related]
3. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
Thompson CI; Barclay WS; Zambon MC
J Antimicrob Chemother; 2004 May; 53(5):759-65. PubMed ID: 15028666
[TBL] [Abstract][Full Text] [Related]
4. The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.
Mishin VP; Sleeman K; Levine M; Carney PJ; Stevens J; Gubareva LV
Antiviral Res; 2014 Jan; 101():93-6. PubMed ID: 24239666
[TBL] [Abstract][Full Text] [Related]
5. Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015.
Tewawong N; Marathe BM; Poovorawan Y; Vongpunsawad S; Webby RJ; Govorkova EA
PLoS One; 2018; 13(1):e0190877. PubMed ID: 29324781
[TBL] [Abstract][Full Text] [Related]
6. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
Little K; Leang SK; Butler J; Baas C; Harrower B; Mosse J; Barr IG; Hurt AC
Euro Surveill; 2015; 20(45):. PubMed ID: 26608955
[TBL] [Abstract][Full Text] [Related]
7. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
[TBL] [Abstract][Full Text] [Related]
8. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
[TBL] [Abstract][Full Text] [Related]
9. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
[TBL] [Abstract][Full Text] [Related]
10. Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.
Tang J; Zhang J; Zhou J; Zhu W; Yang L; Zou S; Wei H; Xin L; Huang W; Li X; Cheng Y; Wang D
Virol J; 2019 Jul; 16(1):87. PubMed ID: 31266524
[TBL] [Abstract][Full Text] [Related]
11. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?
Lin YP; Gregory V; Collins P; Kloess J; Wharton S; Cattle N; Lackenby A; Daniels R; Hay A
J Virol; 2010 Jul; 84(13):6769-81. PubMed ID: 20410266
[TBL] [Abstract][Full Text] [Related]
12. Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.
Gohil DJ; Kothari ST; Shinde PS; Chintakrindi AS; Meharunkar R; Warke RV; Kanyalkar MA; Chowdhary AS; Deshmukh RA
Infect Genet Evol; 2015 Jan; 29():75-81. PubMed ID: 25461259
[TBL] [Abstract][Full Text] [Related]
13. Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
Fujisaki S; Imai M; Takashita E; Taniwaki T; Xu H; Kishida N; Yokoyama M; Sato H; Tashiro M; Odagiri T
J Infect Chemother; 2013 Oct; 19(5):891-5. PubMed ID: 23529501
[TBL] [Abstract][Full Text] [Related]
14. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses.
Yen HL; Hoffmann E; Taylor G; Scholtissek C; Monto AS; Webster RG; Govorkova EA
J Virol; 2006 Sep; 80(17):8787-95. PubMed ID: 16912325
[TBL] [Abstract][Full Text] [Related]
15. Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2.
Trebbien R; Christiansen CB; Fischer TK
J Clin Virol; 2018 May; 102():1-6. PubMed ID: 29448067
[TBL] [Abstract][Full Text] [Related]
16. Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
Bauer K; Dürrwald R; Schlegel M; Pfarr K; Topf D; Wiesener N; Dahse HM; Wutzler P; Schmidtke M
Med Microbiol Immunol; 2012 Feb; 201(1):61-72. PubMed ID: 21688167
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir.
Richard M; Ferraris O; Erny A; Barthélémy M; Traversier A; Sabatier M; Hay A; Lin YP; Russell RJ; Lina B
Antimicrob Agents Chemother; 2011 Jun; 55(6):2942-52. PubMed ID: 21422222
[TBL] [Abstract][Full Text] [Related]
18. Structural and evolutionary characteristics of HA, NA, NS and M genes of clinical influenza A/H3N2 viruses passaged in human and canine cells.
Zhirnov OP; Vorobjeva IV; Saphonova OA; Poyarkov SV; Ovcharenko AV; Anhlan D; Malyshev NA
J Clin Virol; 2009 Aug; 45(4):322-33. PubMed ID: 19546028
[TBL] [Abstract][Full Text] [Related]
19. Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses.
Gulati S; Smith DF; Air GM
Virol J; 2009 Feb; 6():22. PubMed ID: 19216793
[TBL] [Abstract][Full Text] [Related]
20. Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.
Mohr PG; Williams J; Tashiro M; Streltsov VA; McKimm-Breschkin JL
Antiviral Res; 2020 Oct; 182():104895. PubMed ID: 32750469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
